| Project/Area Number |
24300172
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Partial Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Biomedical engineering/Biological material science
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
MURATA Masaharu 九州大学, 学内共同利用施設等, 准教授 (30304744)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
橋爪 誠 九州大学, 医学(系)研究科(研究院), 教授 (90198664)
濱野 展人 九州大学, 先端医療イノベーションセンター, 研究員 (80708397)
河野 喬仁 九州大学, 先端融合医療レドックスナビ研究拠点, 研究員 (90526831)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
HASHIZUME Makoto 九州大学, 大学院医学研究院, 教授 (90198664)
KAWANO Takahito 九州大学, 先端融合医療レドックスナビ研究拠点, 特任助教 (90526831)
HAMANO Nobuhito 九州大学, 先端医療イノベーションセンター研究拠点, 特任助教 (80708397)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2012: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
|
|---|
| Keywords | 分子イメージング / ナノ材料 / MRI / 造影剤 / タンパク工学 / 癌 |
|---|
| Outline of Final Research Achievements |
In this study, small heat shock protein 16.5 (Hsp16.5)-based nanocages conjugated with gadolinium(III)-chelated MRI contrast agents were developed for the diagnosis of pancreatic cancer. Nanocages with one to four hydrophobic domains were designed to investigate whether template size influences relaxivity. MRI data showed that larger nanocages have higher T1 relaxivities than smaller nanocages as a result of 1) a reduction in molecular tumbling rates caused by an increase in nanocage size and 2) a robust cage structure resulting from the introduction of hydrophobic domains. The introduction of iRGD peptides that specifically target neuropilin-1 enabled the selective binding of nanocages to pancreatic cancer cells. Therefore, this iRGD- modified Hsp16.5 nanocage displays great potential as a highly specific and sensitive MRI contrast agent for the diagnosis of pancreatic cancer.
|
